Calcitonin gene-related peptide
Also known as: alpha-CGRP, beta-CGRP, Calcitonin gene-related peptide-I, calcitonin gene‑related peptide (alpha), CGRP, α‑CGRP, β‑CGRP
Source Calcitonin gene-related peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Calcitonin gene‑related peptide (CGRP) is a neuropeptide involved in vascular tone and pain signalling. Research has focused on its role in migraine, where elevated CGRP contributes to headache generation. Therapies that block CGRP or its receptor—monoclonal antibodies and small‑molecule antagonists (gepants)—have shown preventive and acute efficacy in clinical trials.
Mechanism of Action
CGRP binds to a heterodimeric receptor composed of the calcitonin‑like receptor and the receptor‑activity‑modifying protein 1 (RAMP1). Activation triggers intracellular cAMP elevation, leading to vasodilation of cerebral vessels and sensitisation of trigeminal nociceptors. Antagonists or antibodies that prevent CGRP binding interrupt this cascade, reducing vascular dilation and pain signalling associated with migraine attacks.
What the Research Shows
A 2023 network meta‑analysis of 74 trials (32,990 patients) found high‑certainty evidence that monoclonal antibodies targeting CGRP or its receptor, as well as gepants, increase the proportion of patients achieving a ≥50% reduction in monthly migraine days, with a favourable safety profile compared with placebo. The phase 2/3 oral rimegepant trial (2021) demonstrated a mean reduction of 0.8 migraine days per month versus placebo over weeks 9‑12, with adverse‑event rates identical to placebo. The phase 3 atogepant study (2021) showed dose‑dependent reductions of 1.2‑1.7 migraine days versus placebo and reported constipation and nausea as the most common side effects. A 2021 systematic review of acute migraine treatments identified CGRP receptor antagonists as effective for pain relief, with low‑to‑high certainty of benefit. A 2022 fascia innervation review noted CGRP as a frequent immunohistochemical marker, underscoring its widespread nociceptive presence.
Reported Benefits
Blocking CGRP signalling has consistently reduced migraine frequency in preventive trials, achieving clinically meaningful reductions of 1‑2 migraine days per month compared with placebo. Acute CGRP antagonists also improve pain freedom at two hours after attack onset. Safety data from large meta‑analyses and individual trials suggest tolerability comparable to placebo, with most adverse events being mild and transient.
Limitations of the Evidence
Evidence is confined to migraine; data on other pain conditions are limited to immunohistochemical observations. Long‑term safety of chronic CGRP blockade remains incompletely characterised, and rare serious events (e.g., asthma, optic neuritis) were reported in small numbers. Direct clinical data on the peptide itself are lacking, as most studies evaluate antagonists or antibodies rather than CGRP administration. Comparative head‑to‑head trials among different CGRP‑targeting agents are sparse.
Safety Considerations
In the rimegepant preventive trial, overall adverse‑event rates (36%) matched placebo, with no deaths and few discontinuations. Atogepant trials reported constipation (≈7%) and nausea (≈5%) as the most common side effects; serious events were rare (single cases of asthma and optic neuritis). Network meta‑analysis indicated that monoclonal antibodies and gepants do not increase discontinuations due to adverse events, unlike some traditional preventives. Monitoring for gastrointestinal symptoms and rare hypersensitivity reactions is advised.
How It Is Administered
Research formulations of CGRP or its antagonists have been delivered intranasally, intravenously, subcutaneously, and orally. Preventive gepants such as rimegepant are taken every other day, while atogepant is administered once daily. Monoclonal antibodies are typically given by subcutaneous injection at intervals ranging from monthly to quarterly in clinical studies.
Routes of Administration
Goals & Uses
- Migraine prophylaxis targetTherapeutic TargetHigh
- Pain modulation researchResearchModerate
- Wound healing / tissue protectionResearchLow
- Migraine research / provocation modelResearchHigh
- Cardiovascular vasodilation researchResearchModerate
Contraindications
- Severe cardiovascular diseaseCardiovascularHigh
- Active myocardial ischemiaCardiovascularHigh
- Known hypersensitivity to CGRPAllergic/ImmunologicHigh
Adverse Effects
- Injection site reactionsLocalUncommon
- HypotensionCardiovascularUncommonLow blood pressure
- FlushingVascularCommonWarmth and redness of the skin
- Headache / migraineNeurologicalCommon
- Reflex tachycardiaCardiovascularUncommon
Drug Interactions
- NitratesModerate
- Antihypertensive agentsModerate
- Vasoconstrictors (e.g., triptans, ergotamines)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Elderly patients with cardiovascular diseaseCardiovascularRelative
- Pediatric patientsAgeRelative
- Patients with uncontrolled hypertensionCardiovascularRelative
Regulatory Status
- European UnionUnapprovedNot approved as a therapeutic agent by EMA. Used in clinical research settings for migraine provocation studies.
- United StatesUnapprovedCGRP itself is not an approved therapeutic. Anti-CGRP monoclonal antibodies and gepants are FDA-approved for migraine. CGRP is used in IND-covered research protocols.
- United KingdomUnapprovedNot approved by MHRA as a therapeutic. Used experimentally in academic and clinical research.
Not an approved pharmaceutical; used experimentally as a biomarker or in pre‑clinical studies.
Evidence & Sources
- Journal ArticleHighLampl C, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateCroop R, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighVanderPluym JH, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleModerateAilani J, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighSuarez-Rodriguez V, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateLipton RB, et al.2020-01-01T00:00:00.000000Z
Frequently Asked Questions
What role does CGRP play in migraine?
CGRP is released from trigeminal nerves during a migraine attack, causing dilation of cerebral vessels and sensitising pain pathways. Elevated CGRP levels correlate with headache intensity, making it a key target for therapeutic interruption.
Are there approved medicines that target CGRP?
While the peptide itself is not an approved drug, several monoclonal antibodies and oral gepants that block the CGRP receptor have received regulatory approval for migraine prevention and acute treatment in many regions.
What are the most common side effects of CGRP‑blocking drugs?
Clinical trials report mild gastrointestinal effects such as constipation and nausea. Overall adverse‑event rates are similar to placebo, and serious events are rare, but patients should be monitored for unusual allergic or respiratory reactions.
Can CGRP be used for conditions other than migraine?
Current research primarily focuses on migraine. CGRP is a marker of nociceptive innervation in fascia and other tissues, but therapeutic applications beyond headache have not been established in human studies.
How is CGRP‑targeted therapy administered?
Monoclonal antibodies are given by subcutaneous injection (often monthly). Small‑molecule antagonists are available as oral tablets taken daily or every other day. Intranasal or intravenous routes have been explored in research settings.
What is Calcitonin gene-related peptide?
Calcitonin gene‑related peptide (CGRP) is a neuropeptide involved in vascular tone and pain signalling. Research has focused on its role in migraine, where elevated CGRP contributes to headache generation. Therapies that block CGRP or its receptor—monoclonal antibodies and small‑molecule antagonists (gepants)—have shown preventive and acute efficacy in clinical trials.
What is Calcitonin gene-related peptide used for?
Calcitonin gene-related peptide is educationally associated with: Migraine prophylaxis target, Pain modulation research, Wound healing / tissue protection, Migraine research / provocation model, Cardiovascular vasodilation research. Educational only — not medical advice.
How is Calcitonin gene-related peptide administered?
Recorded routes of administration: Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Calcitonin gene-related peptide?
Reported adverse effects include: Injection site reactions, Hypotension, Flushing, Headache / migraine, Reflex tachycardia. This list is not exhaustive — consult a qualified clinician.
Who should avoid Calcitonin gene-related peptide?
Recorded contraindications: Severe cardiovascular disease, Active myocardial ischemia, Known hypersensitivity to CGRP. Consult a qualified clinician before use.